IOL Chemicals & Pharmaceuticals Ltd (IOLCP) Q2FY27 Management Mirror - Sep-2026 Qtr
FY27 Revenue Guidance Raised to 25%+ Growth After Delivering INR 795 Crore in Sep'26 Qtr
In Sep'26 Qtr, consolidated revenue from operations reached INR 795 crore (up 40.1% YoY), pushing H1 FY27 revenue to INR 1,551 crore. Management initially guided in Mar'26 Qtr for 15% top-line growth (around INR 2,700 crore) for FY27, and reaffirmed this 15% to 20% range in Jun'26 Qtr; however, following the strong H1 performance, this guidance has now been upgraded to 25%+ YoY growth for the full year. Going forward, performance in Q3 FY27 and Q4 FY27 is expected to remain consistent with H1 FY27 run rates. Management also indicated that the maximum revenue potential from existing installed capacities at 100% utilization across all products is estimated at INR 3,200 crore to INR 3,300 crore.
4 more themes on the ELITE plan.